Bavarian Nordic Wins $228 Million U.S. Smallpox Vaccine Deal

Bavarian Nordic A/S, Denmark’s largest vaccine maker, won a two-year, $228 million U.S. government contract for a smallpox vaccine that accounts for almost all the company’s revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.